In this study, we performed a screen for genetic translocations in gliomas based on exon-level expression profiles. We identified a translocation in the contactinassociated protein-like 2 (CASPR2) gene, encoding a cell adhesion molecule. CASPR2 mRNA was fused to an expressed sequence tag that likely is part of the nuclear receptor coactivator 1 gene. Despite high mRNA expression levels, no CASPR2 fusion protein was detected. In a set of 25 glioblastomas and 22 oligodendrogliomas, mutation analysis identified two additional samples with genetic alterations in the CASPR2 gene and all three identified genetic alterations are likely to reduce CASPR2 protein expression levels. Methylation of the CASPR2 gene was also observed in gliomas and glioma cell lines. CASPR2-overexpressing cells showed decreased proliferation rates, likely because of an increase in apoptosis. Moreover, high CASPR2 mRNA expression level is positively correlated with survival and is an independent prognostic factor. These results indicate that CASPR2 acts as a tumor suppressor gene in glioma.
Introduction
Gliomas are the most frequently diagnosed type of primary brain tumor in adults, with an incidence of E3.5/100 000 (http://www.cbtrus.org). Depending on the cell type they resemble, gliomas can be subdivided histologically into astrocytomas (As), oligodendrogliomas (ODs) and oligoastrocytomas (OAs), the latter exhibiting features of both astrocytes and ODs. Gliomas can be further subdivided into various grades of malignancy (II-IV), with grade IV tumors (glioblastomas (GBMs)) being the most common and malignant. GBMs can occur de novo (primary GBM) or evolve from lower-grade gliomas (secondary GBM). Despite extensive therapy (a combination of surgery, radiation and/or chemotherapy), all grade II-IV gliomas are eventually fatal, with a median survival time ranging from over 10 years (grade II ODs) to less than 1 year in GBM (Ohgaki and Kleihues, 2005; Louis et al., 2007) .
Causal genetic changes in cancer cells are direct targets for treatment. In GBM, the most frequently affected genes include CDKN2A (50%), EGFR (37%), TP53 (40%) and PTEN (30%) (Parsons et al., 2008) . In lower-grade gliomas, frequent alterations are a loss of heterozygosity on 1p and 19q (Kraus et al., 1995) , and the recently discovered IDH1 mutations (Balss et al., 2008; Gravendeel et al., 2009; Yan et al., 2009 ). Although frequently mutated causal genes have been found, treatments aimed at the molecular changes have thus far had limited success in glioma. To provide new targets for therapy, tumorigenesis has to be understood at the molecular level, and new causal genes and pathways have to be identified.
Genomic translocations that result in the expression of a fusion gene have been implicated in cancer. As such translocations often show aberrant expression of the fusion partners, screening for aberrant expression can identify novel fusion genes (Tomlins et al., 2005) . Exonlevel expression profiling is a method that can identify differentially expressed splice variants (Clark et al., 2007; French et al., 2007) . We have recently shown that genomic mutations in cancer that lead to skipping of one or more exons are also detected by such arrays (Schutte et al., 2008) . Aberrant expression of exons also occurs when translocations lead to a gene fusion and exons from one gene are driven by a promoter from another gene. We therefore screened for such translocations based on exon array data.
Our screen identified the contactin-associated proteinlike 2 (CASPR2) gene, encoding a cell adhesion molecule, as the 3 0 fusion partner of a translocation. In a set of 25 GBMs and 22 ODs, we additionally identified one intragenic deletion and one larger deletion that includes the entire CASPR2 gene. All three identified genetic alterations are likely to reduce CASPR2 protein expression levels. CASPR2 methylation was also observed in gliomas and glioma cell lines. Interestingly, a significant decrease in proliferation rate was observed in cells overexpressing CASPR2-green fluorescence protein (GFP). In addition, high CASPR2 expression is associated with longer survival, and multivariate analysis indicated that CASPR2 mRNA expression level is an independent prognostic factor. The genetic alterations identified, the reduced proliferation rate of CASPR2-GFP-expressing cells and the positive correlation between CASPR2 expression and survival indicate that CASPR2 acts as a tumor suppressor gene in glioma.
Results

Identifying a novel translocation involving EST AI364529 and CASPR2
We have recently demonstrated that exon-level profiling can detect exon-skipping mutants and splice variants (French et al., 2007; Schutte et al., 2008) . In this study, we used these expression profiles to screen for fusion transcripts. We first identified transcripts with aberrant expression ratios between 5 0 and 3 0 exons in 25 GBMs and 22 ODs (see Materials and methods). Eleven genes were found in which the 5 0 /3 0 ratios differed 416-fold from the mean (see for example Figure 1a and Supplementary Table 3) . Visual inspection reduced the number of candidates by eliminating those with, for example, one aberrant probeset expression or those with a highly skewed 5 0 /3 0 expression ratio in all samples. In several of the identified candidates, the altered 5 0 expression was likely caused by transcripts derived from an alternative promoter (data not shown). Transcripts driven from an alternative promoter will also have an altered 5 0 /3 0 expression ratio, and the identification of such transcripts validates our approach.
In GBM142, 5 0 RACE-PCR identified a candidate fusion gene between exon 9 of CASPR2 and an expressed sequence tag (EST AI364529) located on chromosome 2. The EST AI364529-CASPR2 fusion gene was confirmed by reverse transcriptase-PCR using a forward primer in EST AI364529 and a reverse primer in CASPR2 (Figure 1b) . EST AI364529 is located upstream of the nuclear receptor coactivator 1 (NCOA1) gene. Sequence alignment suggests that, similar to mouse Ncoa1, this EST forms part of the human NCOA1 gene (Figure 1c ). The translocation does not appear to affect expression of the NCOA1 gene in GBM142 (Figure 1d) . Apparently, the remaining allele is sufficient to drive normal NCOA1 expression levels. The observation that NCOA1 expression is not altered led us to focus our further experiments on the CASPR2 gene.
Genomic translocations in cancer can result in expression of fusion proteins that act as oncogenes (Heisterkamp et al., 1985; Tomlins et al., 2005) . However, western blot failed to detect expression of the AI364529-CASPR2 fusion protein (Figure 2) . Thus, in spite of high transcript expression levels ( Figure 1a) ; no protein product appears to be expressed. The absence of protein expression may be explained by the absence of a clear translation initiation codon with a consensus Kozak sequence in the fusion transcript. The absence of an EST AI364529-CASPR2 protein expression in GBM142 suggests that the fusion protein does not act as an oncogene.
Mutation screen in CASPR2 Causative genetic changes in cancer often have a significant mutation frequency. We therefore screened for additional mutations in the CASPR2 gene. We first determined whether the specific EST AI364529-CASPR2 translocation occurs in other tumor samples. Using a forward primer in EST AI364529 and a reverse primer in CASPR2, reverse transcriptase-PCR failed to identify this specific translocation in 25 GBMs (Figure 3a) . We then analyzed all exon-expression profiles in detail (25 GBMs and 22 ODs) to identify other candidate breakpoints within the CASPR2 gene. Such candidates may have escaped detection in our initial screen because of focusing on top candidates. In another sample (GBM96), the 5 0 /3 0 exon expression also shows an aberrant ratio (Figure 3b) . However, such profile can be expected when CASPR2 expression is derived from the alternative promoter present between exons 21 and 22 (CR933671). CASPR2 protein expressed from this alternative promoter contains only the last three coding exons and, on the protein level, lacks the extracellular domain. This isoform of CASPR2 apparently does not function as a cell adhesion molecule and may compete with expression of full-length CASPR2 (for protein expression in GBM96, see Figure 2b ).
We then performed mutational analysis of all 24 coding exons of CASPR2 in 23 GBMs and 18 ODs (Supplementary Table 4 ). One heterozygous missense mutation in GBM139 (73 G-A) was identified ( Figure 3c ). This base change causes an alanine amino acid to be replaced by a threonine (A24T). The mutation lies in exon 1, within the conserved region coding for the signaling peptide of CASPR2. The base change is not present in single-nucleotide polymorphism databases, but was present in DNA isolated from the patients' blood sample, indicating that the mutation is not somatic. Western blot detected very low protein expression in GBM139 (Figure 2b) .
We next screened for changes in CASPR2 copy number in the same sample cohort. Copy number changes were inferred from genotyping arrays (Bralten et al., 2010) . As reported previously (Bredel et al., 2005; Freire et al., 2008) , trisomy of the entire chromosome 7 was frequently observed in gliomas. However, in GBM254, genotyping identified a heterozygous deletion of a large region including the entire CASPR2 gene (chr7:102106439-end, Figure 3d ). Interestingly, in OD53, genotyping also identified an intragenic deletion (chr7:146208141-147249840, Figure 3d ) that spans exons 4-14 and will result in a premature termination CASPR2, a tumor suppressor gene in glioma LBC Bralten et al codon in exon 15. No mutations were found in the coding exons of the remaining CASPR2 allele. However, both GBM254 and OD53 had low CASPR2 mRNA expression ( Supplementary Figures 1 and 2 ) and no CASPR2 protein expression ( Figure 2c ).
As intronic CASPR2 deletions have been associated with schizophrenia and epilepsy (Friedman et al., 2008) , intronic deletions may affect CASPR2 function. We therefore screened for small intronic deletions in four samples (in which no base change or large deletion was identified), using custom-made genotyping arrays that span the entire CASPR2 gene. Custom arrays confirmed the trisomy on chromosome 7 in GBM157 in the CASPR2 region. No additional genetic changes were identified using these arrays (data not shown).
As CASPR2 is methylated in pancreatic carcinoma (Omura et al., 2008) , we determined the CASPR2 methylation status of six cell lines (U87, U118, U138, U373, T98 and human embryonic kidney (HEK)) and seven tumor samples. In all glioma cell lines, the CASPR2 gene was methylated and all these cell lines have low CASPR2 mRNA expression. The CASPR2 gene is not methylated in HEK cells, which may explain CASPR2 mRNA expression in these cells (GSE1309). However, western blot analysis failed to detect CASPR2 protein expression in HEK cells (data not shown). Four out of seven tumor samples had CASPR2 methylation, and methylation status correlated with mRNA expression in five out of seven samples. Methylation of the CASPR2 gene, therefore, may be an epigenetic mechanism that downregulates CASPR2 expression in gliomas.
In summary, our comprehensive mutational analysis identified at least three genetic changes in the CASPR2 gene in gliomas: one translocation, one intragenic deletion and one larger deletion in a set of 47 glioma samples. In addition, CASPR2 functioning may also be compromised in GBM96, where expression might be driven from an alternative promoter. The CASPR2 gene is also methylated in a subset of gliomas. At least several of the identified mutations appear to disrupt normal CASPR2 functioning.
CASPR2 overexpression decreases the proliferation rate
The relatively high frequency in which we identified genetic changes in the CASPR2 gene led us to perform functional experiments to determine the role of CASPR2 in glioma formation and/or progression. We first created a CASPR2 construct with a hemagglutinin (HA) epitope inserted directly c-terminal of the signaling peptide domain and enhanced-GFP inserted intracellularly, following the transmembrane domain (Supplementary Figure 3 ). The final HA-CASPR2-GFP construct allowed us to use the extracellular HA tag to CASPR2, a tumor suppressor gene in glioma LBC Bralten et al confirm transmembrane localization using immunocytochemistry (Supplementary Figure 4) . The intracellular GFP tag allowed visualization of the construct in live cells while preserving functioning of the intracellular CASPR2 domain (Horresh et al., 2008) . The construct was then used to create stable HA-CASPR2-GFPexpressing U87MG, U373 and HEK cell lines. U87MG and HEK cells stably expressing HA-CASPR2-GFP showed a decrease in proliferation rate compared with control (DsRed2) expressing cells in a WST-1 cell proliferation assay. The mean reduction in proliferation rate was 13% (range 7.3-22.2%, P ¼ 0.007). This reduction appears to be specific for CASPR2 as other overexpressed enhanced green fluorescent protein fusion genes, in our laboratory do not show a decreased proliferation (LBC Bralten and PJ French, data not shown). We also analyzed co-cultures of U87MG cells that initially contained a mixture of HA-CASPR2-GFP-and DsRed2-expressing cells (see Materials and methods). Cell cycle analysis of the mixture shows a much lower G2 peak in the HA-CASPR2-GFP-expressing cells compared with the DsRed2-expressing cells (Figure 4a ). After 9-10 cell culture passages, the number of HA-CASPR2-GFPexpressing cells in three independent experiments was reduced to 0.3, 0.3 and 4.5%, respectively, of the total number of cells (Figure 4b ). Fluorescence activated cell sorting (FACS) analysis on U87MG mixed cell cultures therefore confirmed the reduced proliferation as observed in our WST-1 cell proliferation assays. To determine the effects of CASPR2 overexpression on cell proliferation in other cell lines, U118, U138, U373, T98 and HEK cells were transfected with HA-CASPR2-GFP or DsRed2. After 3 weeks of culture on selection medium, the percentages of DsRed2-expressing cells were significantly higher than those of the HA-CASPR2-GFP-expressing cells (U118: 94.9 vs 1.5%; U138: 57.6 vs 0.7%; U373: 51.8 vs 5.4%; T98: 9.9 vs 1.3%; HEK: 94.9% vs 18.1%; P ¼ 0.007). These differences are in line with the hypothesis that HA-CASPR2-GFP-expressing cells have a growth disadvantage. The absence of CASPR2 expression in established cell lines (U87MG, U118, U138, U251, U373, U387, SF126, SF268, SF539, A172, SNB19, SNB75, LN229 and T98), according to the GEO datasets (GSE10547, GSE5720 and GSE4536), prohibited knockdown experiments.
We next aimed to determine the mechanism of the CASPR2-associated decrease in proliferation rate. b-Galactosidase assays did not reveal a difference in cellular senescence between U87MG cells expressing HA-CASPR2-GFP and DsRed2 (1.26% and 1.48%, respectively, P ¼ 0.63). The HA-CASPR2-GFP-expressing cells do not show a marked increase in cell volume compared with the DsRed2-expressing cells, arguing against increased CASPR2-associated cellular senescence (Supplementary Figure 5) . However, a 46% increase in apoptosis was observed in HA-CASPR2-GFP-compared with DsRed2-expressing U87MG cells (P ¼ 0.0019). This increase in apoptosis in CASPR2-overexpressing cells may therefore explain the CASPR2-associated reduction in proliferation.
CASPR2 overexpression does not affect migration and invasion Cell adhesion molecules, like neural cell adhesion molecule, are thought to have a role in invasiveness and progression in cancer (Zecchini and Cavallaro, 2010) . As CASPR2 also functions as a cell adhesion molecule, we determined whether CASPR2 expression may affect cell migration and invasion. No difference in migration and invasion of U87MG cell lines was observed both by Millipore migration and invasion assays (Millipore, Billerica, MA, USA; P ¼ 0.25 and 0.38, respectively) and in the Incucyte (migration only) (P ¼ 0.91).
CASPR2 expression is positively correlated with patient survival As CASPR2-overexpressing tumor cells in vitro have a decreased cell proliferation, we looked at survival and CASPR2 mRNA expression in a set of 268 glial brain tumors. CASPR2 mRNA expression was positively correlated with overall survival (Figures 5a and b) . Patients with low CASPR2 expression (less than the median) had a median survival of 0.79 years compared with 2.83 years in the group with high CASPR2 expression (Po0.0001). Even within defined histological subgroups (AIII, AOIII and ODIII), patients with high CASPR2 expression (greater than the median) had a significantly better survival than patients with low CASPR2 expression (less than the median) (P ¼ 0.0197, 0.0371 and 0.0001, respectively). Similarly, the survival of GBM patients with high CASPR2 expression (top 25th percentile) was significantly longer than that of other GBM patients (P ¼ 0. Table 6 ). Furthermore, CASPR2 immunocytochemistry on GBM163 and GBM207 confirmed that CASPR2 is expressed by tumor cells and is not due CASPR2, a tumor suppressor gene in glioma LBC Bralten et al to a contamination of non-neoplastic brain tissue (Figure 2d ). Multivariate analysis demonstrated that CASPR2 expression is a prognostic factor that is independent of histological diagnosis (including subtype and grade), age and Karnofsky performance score (P ¼ 0.009) ( Table 1) .
Discussion
In this paper, we describe a novel translocation involving the CASPR2 gene using exon-expression arrays. CASPR2 was fused with an EST (EST AI364529) that is likely to be part of the NCOA1 gene. The fusion of this EST and CASPR2 resulted in loss of CASPR2 protein expression, despite high mRNA expression. Mutation analysis of CASPR2 revealed at least two other glioma samples with inactivating mutations. Methylation of the CASPR2 gene was also observed in gliomas and glioma cell lines. Furthermore, lower proliferation rates were observed after CASPR2 overexpression in glioma cell lines, most likely due to an increase in apoptosis in these cells. Finally, multivariate analysis showed that high CASPR2 expression is positively correlated with patient survival. Our results are consistent with CASPR2 functioning as a tumor suppressor gene in gliomas.
The CASPR2 gene spans a region of 2.3 Mb on chromosome 7. It encodes CASPR2, a transmembrane cell adhesion molecule and member of the neurexin superfamily. Extracellularly, CASPR2 binds to contactin 2 (TAG-1), a neural recognition protein of the immunoglobulin cell adhesion molecule superfamily (Poliak et al., 2003) . The CASPR2-contactin 2 complex is involved in clustering of K þ channels in the juxtaparanodal region of the nodes of Ranvier (Poliak et al., 2003) and in neurite outgrowth (Lieberoth et al., 2009) . Germline genetic alterations in the CASPR2 gene have been found in several neurological and psychiatric diseases, including recessive symptomatic focal epilepsy and autism (Strauss et al., 2006; Bakkaloglu et al., 2008; Jackman et al., 2009) , combined schizophrenia and epilepsy (Friedman et al., 2008) and Gilles de la Tourette's syndrome with obsessive-compulsive disorder (Verkerk et al., 2003) . All genetic alterations found were inactivating. Furthermore, linkage studies have identified single-nucleotide polymorphisms in CASPR2 that predispose for autism (Alarcon et al., 2008; Arking et al., 2008) and language impairments (Vernes et al., 2008) . These studies emphasize the importance of CASPR2 in the central nervous system. Several other studies have highlighted a potential role of CASPR2 in cancer formation and/or progression. First, Thorell et al. suggest CASPR2 to be a tumor suppressor gene; they show a fivefold lower CASPR2 expression in unfavorable neuroblastomas compared with favorable neuroblastomas (Thorell et al., 2009) . CASPR2 was the gene with the largest change in expression found between these two groups (Thorell et al., 2009) . Second, CASPR2 is a common integration site of the sleeping-beauty transposon in sarcomas from ArfÀ/À mice (Collier et al., 2005) . In three independent sarcomas, the transposon disrupted the coding sequence of CASPR2 (Collier et al., 2005) . Finally, CASPR2 is methylated in 82% (47/57) of the pancreatic cancers, compared with 3% (1/34) of the cases of normal pancreas tissue (Omura et al., 2008) . In our group of 268 gliomas, CASPR2 expression was heterogeneous (Figure 5b) and methylation of the CASPR2 gene could in part be an explanation for the remaining lowexpressing samples. More generally, the CASPR2 gene is part of a common fragile site . Such fragile sites are frequently disrupted in cancer and are thought to contain tumor suppressor genes . In summary, disruption of the CASPR2 gene has been reported in several cancer subtypes, as well as in various neurological and psychiatric disorders. Disruptive genetic changes were also identified in the present study.
With its intracellular domain, CASPR2 binds to the 4.1B protein (Denisenko-Nehrbass et al., 2003) , which is also known as DAL-1 (Differentially expressed in Adenocarcinoma of the Lung). DAL-1 is a member of the protein 4.1 family and acts as a tumor suppressor in meningiomas (Gutmann et al., 2000) . Another wellknown member of the protein 4.1 family in brain cancer is schwannomin (merlin), the product of the NF2 tumor suppressor gene. Loss of heterozygosity of the DAL-1 region was found in 39% of gliomas (Tran et al., 1998) . DAL-1 forms a functional complex with CASPR2. This complex is thought to be involved in cell signaling through the activation of c-Jun amino-terminal kinase, a regulator of the retinoblastoma protein (Gerber et al., 2006) . The mechanism of action of CASPR2 as a tumor suppressor gene may be similar to that of DAL-1. Apparently, CASPR2 is part of a complex that, when inactivated, is involved in tumorigenesis.
CASPR2 is predominantly expressed in cells of neuronal origin (Poliak et al., 1999; Lieberoth et al., 2009) . As gliomas are thought to be of non-neuronal origin, we examined whether the CASPR2 protein is also expressed in glial cells. Immunocytochemistry, using antibodies against CASPR2 and the glial marker GFAP or Vimentin on primary cultured rat hippocampus, indeed confirmed that a subpopulation of glial cells (7 and 4%, respectively) express CASPR2 ( Supplementary  Figure 8) . In whole rat brain, however, CASPR2 and GFAP expression are seldomly colocalized (Supplementary Figure 9) . As CASPR2 is expressed in a subset of cultured rat hippocampal glial cells and in certain gliomas, it is possible that certain gliomas originate from or dedifferentiate in the direction of this subpopulation of glial cells.
NCOA1, the 5 0 fusion partner of the translocation, has also been reported in cancer. NCOA1 is a transcriptional co activator for steroid and nuclear hormone receptors. In GBM NCOA1 is a frequent breakpoint (Freire et al., 2008) , and in alveolar rhabdomyosarcoma NCOA1 was reported as an alternative for FKHR as a translocation partner of PAX3 (Wachtel et al., 2004) . These data indicate that the NCOA1 region is a site with genomic instability in cancer. However, the translocation does not affect the expression of NCOA1 (Figure 1d ), which suggests that NCOA1 does not have a role in our sample cohort.
Although our method of detecting translocations proved to be successful, rigorous testing remains to be done. However, compared with other ways of screening for gene rearrangements (Tomlins et al., 2005; Maher et al., 2009) , our method may provide a cost-effective alternative that does not require large amounts of sample or depend on large-sample cohorts.
In summary, the absence of protein expression resulting from the translocation in GBM142, the intragenic deletion in OD53, the reduced proliferation rate of CASPR2-expressing cells and the positive correlation between CASPR2 expression and survival indicates that CASPR2 functions as a tumor suppressor gene in gliomas
Materials and methods
Sample collection
All glioma samples were derived from patients diagnosed between 1988 and 2004 and treated at the Erasmus Medical Center. All histological diagnoses were made on formalinfixed, paraffin-embedded hematoxylin and eosin-stained sections by an experienced neuropathologist (JMK) (Kleihues and Cavenee, 2000) . Samples were collected immediately after surgical resection, snap-frozen and stored at À80 1C. All samples were visually inspected on 5-mm paraffin-embedded hematoxylin and eosin-stained frozen sections by the neuropathologist (JMK) to ensure 470% tumor content. Use of material was approved by the Institutional Review Board. Non-diseased adult cortical brain samples were obtained from the Erasmus University Medical Center (n ¼ 4) and the Dutch Brain Bank (n ¼ 3) or purchased (n ¼ 1; Qiagen, Venlo, The Netherlands) as described (Gravendeel et al., 2009 ).
RNA, DNA and protein isolation
Tissues adjacent to the paraffin-embedded hematoxylin and eosin-stained frozen sections were used for nucleic-acid isolation as described (French et al., 2007) . For this study, we also isolated protein from the Trizol fraction according to the manufacturer's protocol (Invitrogen, Breda, The Netherlands). RNA quality was assessed on a Bioanalyser (Agilent Technologies, Amstelveen, The Netherlands). High-quality RNA (that is, RNA integrity number 47.0; Schroeder et al., 2006) was used for our experiments. All genomic DNA was amplified using a REPLI-g mini kit (Qiagen).
Arrays
Identification of translocation candidates made use of exonlevel expression profiles reported in French et al. (2007) and Schutte et al. (2008) . This dataset, GSE9385, consists of 26 GBMs, 22 ODs and 6 control samples. CASPR2 copy number was inferred from genotyping arrays performed on 21 GBMs and 19 ODs using 250k NspI arrays (Affymetrix, Santa Clara, CA, USA) (Bralten et al., 2010) . Survival analysis made use of clinical data and expression profiles from a cohort of 268 glioma samples (GSE16011: 117 GBM, 30 AIII, 23 AOIII, 45 ODIII, 16 AII, 7 AOII, 19 ODII and 11 AI; Supplementary Table 1) on U133 plus 2.0 arrays (Affymetrix) described in Gravendeel et al. (2009) . Ultra-high resolution copy number variation analysis of a 2.91-Mb genomic region containing the complete CASPR2 gene was performed on four samples (GBM56, GBM96, GBM142 and GBM157) using a custom NimbleGen microarray (Roche NimbleGen Systems, Madison, WI, USA). The average probe distance for this region was 23 bp.
Identification of fusion genes
The signal intensity estimate and the P-value for each probeset were extracted from the Human Exon 1.0 ST arrays in Affymetrix genotyping console software using RMA. We then screened for candidate fusion genes based on aberrant expression ratios between 5 0 and 3 0 exons. We first excluded exons with low expression levels in all samples (that is, expression levels o6.5). We then excluded exons that show poor correlation with the estimated transcript expression level (metaprobeset level), that is, those with a correlation o0.65. We then calculated the average ratio between the two 5 0 and two 3 0 probesets. Ratios deviating 416-fold from the median ratio were marked as strong candidate fusion partners. All remaining candidates were visually inspected for aberrant expression. 5 0 and 3 0 rapid amplification of cDNA ends (RACE)-PCR was performed using the Marathon RACE Kit (Clontech, Mountain View, CA, USA) according to the manufacturer's protocol. All primers were from Invitrogen and were designed using Primer3 (biotools.umassmed.edu/bioapps/primer3_www. cgi) (Supplementary Table 2 ).
Western blotting
Approximately 2 mg protein was loaded onto 10% polyacrylamide gels, and blotted onto a Hybond-C super nitrocellulose membrane (Amersham Biosciences, Roosendaal, The Netherlands). Membranes were incubated in rabbit-anti-CASPR2 polyclonal antibody (Chemicon International, Temecula, CA, USA) (1:1000) or mouse-anti-tubulin monoclonal antibody (Sigma, St Louis, MO, USA) (1:3000). Membranes were then incubated with either horseradish peroxidase-conjugated polyclonal swine-anti-rabbit (Dako, Glostrup, Denmark) (1:2500) or polyclonal rabbit-anti-mouse (Dako) (1:2500). Detection was carried out using the Amersham ECL advance western blotting detection kit (GE Healthcare, Diegem, Belgium).
PCR amplification and bisulfite sequencing
All 24 coding exons of CASPR2 were amplified by PCR in 23 GBMs and 18 ODs. The sequence could be evaluated in a total of 527/552 and 318/432 exons in GBMs and ODs, respectively. In 25 GBMs a PCR was performed with a forward primer designed in EST AI364529 and a reverse primer designed in exon 9 of CASPR2. Primers and PCR conditions are listed in Supplementary Table 2. Genomic DNA of six cell lines (U87MG, U118, U138, U373, T98 and HEK) and seven glioma samples (four GBM, three ODIII), extracted using Qia-amp DNA mini kits (Qiagen), was bisulfite treated using the MethylEasy DNA Bisulphite Modification Kit (Human Genetic Signatures, Sydney, New South Wales, Australia) according to the manufacturer's protocol. Samples with 425% methylation on evaluable CpG island were considered methylated. PCR primers and conditions to determine CASPR2 methylation were performed as described (Omura et al., 2008) . Amplified products were sequenced using the Big Dye Terminator v3.1 (v1.1 for bisulfite-treated samples) Cycle Sequencing Kit (Applied Biosystems, Nieuwekerk a/d IJssel, The Netherlands). Samples were analyzed using Mutation Surveyor V2.51 (SoftGenetics, State College, PA, USA). Constructs CASPR2 cDNA (Origene Technologies, Rockville, MD, USA) was fused to HA and GFP as outlined in Supplementary  Figure 1 . Our construct preserved the N-terminally localized signal peptide and the C-terminally located PDZ domain (see also Horresh et al., 2008) . Primers and conditions are stated in Supplementary Table 2 . HA-CASPR2-GFP was cloned into the pcDNA3.3-TOPO vector (Invitrogen). The control construct consisted of the DsRed2 gene cloned into the pcDNA3.3-TOPO vector.
Cell lines U87MG, U118, U138, U373, T98 and HEK cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (GIBCO, Breda, The Netherlands) supplemented with 10% fetal calf serum and antibiotics (penicillin and streptomycin) at 37 1C, in a 5% CO 2 humidified chamber. For each cell line two 10-cm Petri dishes were transfected with 15 mg HA-CASPR2-GFP or DsRed2 using FuGENE 6 (Roche, Woerden, The Netherlands) or, in the case of HEK cells, Polyethylenimine 'Max' (Polysciences, Eppelheim, Germany). After 2 days cell cultures were supplemented with 600 mg/ml (U87MG) or 400 mg/ml (U118, U138, U373, T98 and HEK) Geneticin (Invitrogen). CASPR2 mRNA levels in the stable U87MG cell line were 1.7 times higher than the levels in control brain, as was determined by quantitative PCR using SYBR green PCR master mix (Applied Biosystems; French et al., 2005) . CASPR2 expression levels were evaluated relative to GAPDH expression. All primers had an amplification efficiency 480% (determined by serial dilution) and generated a single amplification product (determined by melting point analysis).
FACS sorting and cell cycle analysis
After 3 weeks in selection medium, HA-CASPR2-GFP and/or DsRed2 expressing U87MG (in triplicate), U373 and HEK cells were FACS sorted (FACSAria, BD Biosciences, San Jose, CA, USA) into wells containing 10 000 HA-CASPR2-GFP cells, 10 000 DsRed2 cells, or a mixture of 5000 HA-CASPR2-GFP cells and 5000 DsRed2 cells (U87MG cells only). Parallel sorted cells were analyzed for sorting efficiency (496%) and stained with Hoechst 33258 (Sigma) to analyze viability (480%). FACS-sorted cells were either isolated alive and stained with 20 mg/ml Hoechst 33342 (Sigma) for 20 min at 37 1C (U87MG) or fixed with 4% PFA and stained with 20 mg/ml Hoechst 33258 (Sigma) for 1 h at 37 1C. The mixture of stable U87MG cells was fixed in 75% ethanol. Ki-67 expression was detected using rabbit-anti-Ki67 (1:100) (Abcam, Cambridge, UK) and an antigen-presenting cell-conjugated donkey-anti-rabbit antibody (1:200) (Jackson ImmunoResearch, Suffolk, UK).
Assays U87MG cells expressing either HA-CASPR2-GFP or DsRed2 were plated in two 96-well plates in three different concentrations (200, 400 and 800 cells/well), in triplo, for all three independently sorted cell populations. HEK cells expressing either HA-CASPR2-GFP or DsRed2 were plated at 1000 cells/ well, in triplo, and the experiment was performed in duplo. The percentage of cells expressing HA-CASPR2-GFP or DsRed2 was determined using FACS (U87MG-HA-CASPR2-GFP: 26.1-69.5%, DsRed2: 69.6-99.1%; HEK-HA-CASPR2-GFP: 47.9%, DsRed2: 97.4%). The cell proliferation reagent WST-1 (Roche) was added (1:10) at either 4 h or 3 days after plating. Absorbance was measured in a microplate reader (Multiskan Ascent, Thermo Electron Corporation, Breda, The Netherlands) at 440 nm every 30 min for 3.5 h. The WST-1 reaction is linear in this timeframe; therefore, the slope of the trend line of the absorbance data was used as a measure of viability. The relative increase in this slope after 3 days was used as a measure of proliferation. 24-Well Cell Migration and Invasion Assay Kits (both from Millipore) were used according to the manufacturer's protocol on 0.5 Â 10 6 stable and sorted U87MG cells for 3 days. Results were quantified by colorimetric reading at 560 nm. Migration was also determined using an Incucyte (Essen Instruments, Hertfordshire, UK), for 72 h, at one frame per hour. MTrackJ, a plug-in of the ImageJ software, was used to quantify cell movement.
Apoptosis of stable and sorted U87MG cells was determined using the Cell Death Detection ELISA Kit (Roche) according to the manufacturer's protocol. Thousand cells per well were plated in a 96-well plate and left for 3 days before the start of the protocol. The experiment was performed two times in triplo with two independently sorted sets of stable cell lines. Senescence was detected in U87MG cells using the Senescence b-Galactosidase Staining Kit (Cell Signaling, Bioke´, Leiden, The Netherlands) according to the manufacturer's protocol. Two independently sorted stable cell lines were grown on chamber glasses in duplo for 3 days and stained with 250 ml staining solution.
Immunocytochemistry
Primary rat hippocampal E18 cell cultures, prepared as described in Jaworski et al. (2005) , were fixed after 26 days in culture with 4% paraformaldehyde. In addition, sections of normal rat brain and two gliomas (GBM163 and GBM 207) with high CASPR2 protein expression were fixed with ethanol. Cultures and sections were incubated with mouse-anti-GFAP monoclonal antibody (1:20 000) (Sigma) or mouse-anti-Vimentin monoclonal antibody (1:200) (Sigma) and rabbit-anti-CASPR2 polyclonal antibody, at dilutions of 1:100 for cultures and 1:2000 for sections (Chemicon International). To check for membrane localization of HA-CASPR-GFP, transfected U87MG cells were incubated with mouse-anti-HA (1:1000) (Abcam). Secondary antibodies used were Alexa Fluor 488 goat-anti-rabbit IgG or Alexa Fluor 568 goat-anti-mouse, at dilutions of 1:2500 for cultures and 1:400 for sections and extracellular staining (both from Invitrogen). Slides were mounted with Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA).
Survival analysis
Kaplan-Meier survival analysis was performed with GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA), using a log-rank (Mantel-Cox) test. Multivariate analysis using Cox regression and the Breslow method for ties was performed using STATA 11.0 (StataCorp LP, College Station, TX, USA).
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